title: Low expression of the myeloid differentiation antigen CD65s, a feature of poorly differentiated AML in older adults: study of 711 patients enrolled in ECOG trials.
abstract: CD65s appears when the progenitor antigen CD34 disappears, suggesting that this sialylated carbohydrate antigen marks a turning point in normal myeloid differentiation. We characterized acute myeloid leukemia (AML) with low CD65s expression (CD65s(low) AML) in 711 patients entered on seven Eastern Cooperative Oncology Group AML treatment trials (1986-1999). Of those, 198 (28%) qualified as having CD65s(low) AML. Morphologically, CD65s(low) AML was more common in FAB subgroups with minimal differentiation, M0/M1 (P=<0.0001). Early precursor antigens CD34, CD117 and terminal transferase were more frequent in CD65s(low) than CD65s(high) AML (P=<0.0001). Myeloperoxidase was present in fewer CD65s(low) myeloblasts, and the more mature myeloid antigens, CD15 and CD11b, were rarely detected (P=<0.0001). Yet, the two diagnoses did not differ in the distribution of cytogenetic prognostic groups or the occurrence of the multidrug-resistance mediator, P-glycoprotein. CD65s(low) AML patients were significantly older than CD65s(high) cases (P<0.0001). Furthermore, the incidence of CD65s(low) cases increased with age, from 20% in patients under the age of 50 years to 67% in patients older than 80 years (P<0.0001). Overall, complete remission (CR) rate and overall survival were comparable in CD65s(low) and CD65s(high) AML. However, among patients >55 years of age, CD65s(low) AML had a decreased CR rate of 33 vs 44% in CD65s(high) AML (P=0.055). Thus, CD65s(low) AML represents immunophenotypically undifferentiated disease and occurs predominantly in older adults. Although not statistically significant, the observed association between low CD65s expression and decreased CR rate only in patients over the age of 55 is intriguing.
authors.affiliation: Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY 10466, USA.
authors.forename: E
authors.initials: E
authors.lastname: Paietta
authors.forename: D
authors.initials: D
authors.lastname: Neuberg
authors.forename: J M
authors.initials: JM
authors.lastname: Bennett
authors.forename: G
authors.initials: G
authors.lastname: Dewald
authors.forename: J M
authors.initials: JM
authors.lastname: Rowe
authors.forename: P A
authors.initials: PA
authors.lastname: Cassileth
authors.forename: L
authors.initials: L
authors.lastname: Cripe
authors.forename: M S
authors.initials: MS
authors.lastname: Tallman
authors.forename: P H
authors.initials: PH
authors.lastname: Wiernik
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000032:analysis; D000208:Acute Disease; D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000032:analysis; D015214:Antigens, Differentiation, Myelomonocytic / Q000032:analysis*; D015415:Biomarkers / Q000032:analysis; D002454:Cell Differentiation; D006801:Humans; D016130:Immunophenotyping; D007951:Leukemia, Myeloid / Q000175:diagnosis / Q000401:mortality / Q000473:pathology*; D008875:Middle Aged; D022423:Myeloid Cells / Q000378:metabolism / Q000473:pathology*; D009195:Peroxidase / Q000032:analysis; D011379:Prognosis; D012074:Remission Induction; D015996:Survival Rate
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D015415:Biomarkers; C477320:CD65s antigen, human; D009195:Peroxidase